AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03156322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
Study NCT01547988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training Intervention
Description: The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
Study NCT01547988 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Balance Training Intervention
Description: The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
Study NCT00158340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help cognitive behavioral therapy (CBT)
Description: Participants receive eight sessions of guided self-help CBT.
Study NCT00158340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical care
Description: Control group participants receive treatment as usual.
Study NCT01665339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preload diet
Description: All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
Study NCT01665339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control diet
Description: All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
Study NCT04659395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency nurses
Description: Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
Study NCT03009682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack.
Study NCT02234063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Genetic Testing
Description: Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
Study NCT05555992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study NCT03607188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
Study NCT03120689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Surgery using VITOM
Description: The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
Study NCT03120689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Surgery without VITOM
Description: The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
Study NCT03120689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video viewing with VITOM
Description: They will view the 10-minute standardized video filmed with the VITOM® camera.
Study NCT03120689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video viewing with standard handheld high-definition camera
Description: They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
Study NCT02596126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular Polypill
Description: Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
Study NCT02596126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Prevention for Secondary CV
Description: ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Study NCT04842214 — intervention group
Intervention type: BEHAVIORAL
Intervention: Oncological Rehabilitation
Description: Multidimensional rehabilitation
Study NCT02467517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02467517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Study NCT02467517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo : sodium chloride
Study NCT01715610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clavulin
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator.
Study NCT01715610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Randomization to Placebo
Description: Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
Study NCT01715610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator
Study NCT04402437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LP Block
Description: Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
Study NCT04402437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
Study NCT04192084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microvascular partial toe transfer
Description: we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
Study NCT00069784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
Study NCT00069784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (PUFA)
Description: Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
Study NCT00069784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration
Study NCT00069784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration
Study NCT00069784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reusable pen device for insulin injection
Study NCT02848430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Humulus lupulus
Description: Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
Study NCT03952221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous ultrasound therapy
Description: continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
Study NCT03952221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound therapy
Description: pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
Study NCT03952221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: US and electrotherapy (sonotens)
Description: US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
Study NCT03952221 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham ultrasound therapy
Description: sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
Study NCT03573908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule
Study NCT03573908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide
Description: Oral capsule
Study NCT03573908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo oral capsule
Study NCT03573908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsule
Study NCT00118092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00118092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01741454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.
Study NCT01741454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.
Study NCT01741454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: 4 mg by mouth once a day.
Study NCT02669095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lenses (Test)
Study NCT02669095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lenses (Control)
Study NCT04345458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prefilled liquid etanercept(Yisaipu)
Study NCT04345458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyophilized etanercept powder(Yisaipu)
Study NCT00732602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP-infusion
Study NCT00732602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium-chloride
Study NCT00732602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-2 infusion
Study NCT01555164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine tablet(s) administered orally
Study NCT01555164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ranolazine
Description: Placebo to match ranolazine for the duration of the study
Study NCT01555164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin tablet(s) administered orally once daily
Study NCT01555164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablet(s) administered orally once daily
Study NCT01555164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match metformin
Description: Placebo to match metformin for the duration of the study
Study NCT01555164 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.
Study NCT01555164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.
Study NCT01555164 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study NCT01555164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study NCT02974816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko's mobile application
Description: Standard of care and Remote monitoring
Study NCT00420758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement: fortified spread
Description: Provision of fortified spread
Study NCT00420758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement: maize-soy flour
Description: Provision of corn-soy blend (maize-soy flour)
Study NCT03034499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port sacrocolpopexy
Description: Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
Study NCT03034499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port sacrocolpopexy
Description: Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
Study NCT04131790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Behavioral Activation
Description: Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
Study NCT04131790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-Friendly Visiting
Description: Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
Study NCT00849004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone gel
Description: silicone gel
Study NCT00849004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone sheet
Description: silicone sheet
Study NCT00849004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper tape
Description: paper tape
Study NCT01661556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole
Description: Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
Study NCT01661556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone
Description: Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
Study NCT03937440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular block with 'rocunium®'
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
Study NCT02678325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized high protein enteral nutrition
Description: A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
Study NCT02678325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized normal protein enteral nutrition
Description: double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
Study NCT01518946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine HCl
Description: dose at the subject's current dose level
Study NCT01623635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections).
Study NCT01623635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (normal saline)
Description: ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections).
Study NCT02074098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Direct Laryngoscope
Study NCT01518946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of matching placebo
Study NCT02074098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope
Description: Videolaryngoscope-1
Study NCT02074098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airwayscope
Description: Videolaryngoscope-2
Study NCT01198561 — intervention group
Intervention type: DEVICE
Intervention: repetitive Transcranial Magnetic Stimulation
Description: 10 times repetitive TMS, high frequency
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Intravenous Injection
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous Injection
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation